Denisenko Andrew, Somani Bhaskar, Agrawal Vineet
Geisinger Commonwealth School of Medicine, Pennsylvania, United States.
University Hospital Southampton NHS Trust, Southampton, United Kingdom.
Turk J Urol. 2022 Jan;48(1):11-16. doi: 10.5152/tud.2022.21149.
Recent years have seen a steep rise in minimally invasive surgical therapy (MIST) for benign prostate hyperplasia (BPH). Prostatic urethral lift (UroLift) is a mechanical intervention aimed at reducing lower urinary tract symptoms, which affect patients with BPH.
A narrative synthesis of all studies regarding UroLift is performed over the last decade, evaluating its impact on International Prostate Symptom Score (IPSS), quality of life (QoL), Qmax, Benign Prostate Hypertrophy Impact Index, and sexual health metrics.
The studies included have demonstrated significant improvements in the objective parameters measured. UroLift has a low side-effect profile and is comparable to transurethral resection of the prostate in QoL changes and is superior with respect to recovery time and ejaculatory function.
Our findings suggest that UroLift may be an appropriate treatment for individuals undergoing treatment for BPH who are concerned with sexual and ejaculatory functions. More studies are needed to determine who is eligible for UroLift, as well as the long-term impact of UroLift on individuals with BPH.
近年来，良性前列腺增生（BPH）的微创外科治疗（MIST）急剧增加。前列腺尿道悬吊术（UroLift）是一种旨在减轻下尿路症状的机械干预措施，这些症状会影响BPH患者。
对过去十年中所有关于UroLift的研究进行叙述性综述，评估其对国际前列腺症状评分（IPSS）、生活质量（QoL）、最大尿流率（Qmax）、良性前列腺增生影响指数和性健康指标的影响。
纳入的研究表明，所测量的客观参数有显著改善。UroLift的副作用较小，在生活质量变化方面与经尿道前列腺切除术相当，在恢复时间和射精功能方面更具优势。
我们的研究结果表明，对于关注性功能和射精功能的BPH患者，UroLift可能是一种合适的治疗方法。需要更多研究来确定哪些人适合UroLift，以及UroLift对BPH患者的长期影响。
